A chemotherapy-free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma.

IF 5.1 2区医学 Q1 HEMATOLOGY

British Journal of Haematology Pub Date : 2025-04-02 DOI:10.1111/bjh.20041

Paolo Lopedote, Geoffrey Shouse, Sandrine Puverel, Alexandra Muir, Carly Roleder, Peter Sportelli, Hari Miskin, Lu Chen, Tycel J Phillips, Alexey V Danilov

引用次数: 0

查看原文本刊更多论文

阿卡拉布替尼、umbralisib和ublituximab的无化疗方案在未经治疗的套细胞淋巴瘤患者中获得了高缓解率和检测不到的微小残留疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Haematology 医学-血液学

CiteScore

8.60

自引率

4.60%

发文量

565

审稿时长

1 months

期刊介绍： The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.